Department of Morphological Sciences, University of Cordoba Medical School, Cordoba, Spain.
Maimonides Biomedical Research Institute of Cordoba, E-14004, Cordoba, Spain.
Virchows Arch. 2022 May;480(5):989-998. doi: 10.1007/s00428-021-03264-6. Epub 2022 Feb 4.
The aim of the study was to stratify high-grade T1 (HGT1) bladder urothelial carcinoma into risk categories based on the presence of variant histology when compared to conventional urothelial carcinoma. The clinicopathological features of 104 HGT1 cases of urothelial carcinoma of the bladder with variant histology present in 34 (37%) were assessed. The endpoint of the study was disease-free survival and cancer-specific survival. Overall, variant histology was identified as a significant predictor of disease-free survival (P = 0.035). The presence of any specific variant histology (squamous, glandular, micropapillary, nested, microcystic, inverted growth, villous-like, basaloid, and lymphoepithelioma-like) was identified as a significant predictor of disease-free survival (P = 0.008) and cancer-specific survival (P = 0.0001) in HGT1 bladder cancer. Therefore, our results support including micropapillary HGT1 urothelial carcinoma within the aggressive high-risk category, as suggested by some recent clinical guidelines, but also favor nested, glandular, and basaloid to be placed in the high-risk category due to their potential of aggressive, life-threatening behavior and their limited response to bacillus Calmette-Guerin therapy. Conversely, the low-risk category would include urothelial carcinomas with squamous, inverted growth, or microcystic morphology, all with limited life-threatening potential and good response to current therapy. A very low-risk category would finally include patients whose tumors present villous-like or lymphoepithelioma-like morphology. In conclusion, our findings support the value of reporting the variant histology as a feature of variable aggressiveness in HGT1 urothelial carcinoma of the bladder.
本研究旨在根据异型组织学的存在,将高级别 T1(HGT1)膀胱尿路上皮癌分为不同的风险类别,与传统的尿路上皮癌相比。评估了 34 例(37%)存在异型组织学的 104 例 HGT1 膀胱尿路上皮癌的临床病理特征。研究的终点是无病生存率和癌症特异性生存率。总的来说,异型组织学被确定为无病生存率的显著预测因素(P=0.035)。任何特定异型组织学(鳞状、腺体、微乳头状、巢状、微囊性、倒置生长、绒毛状、基底样和淋巴上皮样)的存在被确定为 HGT1 膀胱癌无病生存率(P=0.008)和癌症特异性生存率(P=0.0001)的显著预测因素。因此,我们的结果支持将高侵袭性高危类别中的微乳头状 HGT1 尿路上皮癌纳入其中,正如一些最近的临床指南所建议的,也支持将巢状、腺体和基底样纳入高危类别,因为它们具有侵袭性、危及生命的行为的潜力,并且对卡介苗治疗的反应有限。相反,低危类别将包括具有鳞状、倒置生长或微囊性形态的尿路上皮癌,所有这些都具有有限的危及生命的潜力和对当前治疗的良好反应。最后,极低危类别将包括肿瘤呈绒毛状或淋巴上皮样形态的患者。总之,我们的研究结果支持在 HGT1 膀胱尿路上皮癌中报告异型组织学作为可变侵袭性特征的价值。